Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to Be Acquired by Novartis for Up to $3.1 Billion
February 13, 2025
February 13, 2025
NEW YORK, Feb. 13 -- Blackstone, an investment firm, issued the following news release:
* * *
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion
Reflects the promise of the novel Factor XI inhibitor class of medicines to help prevent strokes and other conditions as well as Abelacimab's potential to provide superior safety
Culminates growth journey as part of Blac . . .
* * *
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion
Reflects the promise of the novel Factor XI inhibitor class of medicines to help prevent strokes and other conditions as well as Abelacimab's potential to provide superior safety
Culminates growth journey as part of Blac . . .